Travis J Hollmann
Overview
Explore the profile of Travis J Hollmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
4977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Caeser R, Egger J, Chavan S, Socci N, Jones C, Kombak F, et al.
Nat Commun
. 2022 Apr;
13(1):2144.
PMID: 35440124
Access to clinically relevant small cell lung cancer (SCLC) tissue is limited because surgical resection is rare in metastatic SCLC. Patient-derived xenografts (PDX) and circulating tumor cell-derived xenografts (CDX) have...
22.
Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
Vanguri R, Benhamida J, Young J, Li Y, Zivanovic O, Chi D, et al.
Gynecol Oncol Rep
. 2022 Feb;
39:100926.
PMID: 35146104
Objectives: We quantitatively characterized the change in temporospatial expression of repressive and stimulatory checkpoints across immune cell populations in the tumor microenvironment in a cohort of high grade serous ovarian...
23.
Friedman C, Spencer C, Cabanski C, Panageas K, Wells D, Ribas A, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35074903
Background: There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with...
24.
Pourmaleki M, Jones C, Ariyan C, Zeng Z, Pirun M, Navarrete D, et al.
Cancer Immunol Res
. 2022 Jan;
10(3):303-313.
PMID: 35013003
Cancer immunotherapy can result in lasting tumor regression, but predictive biomarkers of treatment response remain ill-defined. Here, we performed single-cell proteomics, transcriptomics, and genomics on matched untreated and IL2 injected...
25.
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan Y, Chavan S, et al.
Cancer Res
. 2021 Nov;
82(3):472-483.
PMID: 34815254
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet...
26.
Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O, et al.
Cancer Cell
. 2021 Oct;
39(11):1479-1496.e18.
PMID: 34653364
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, respectively). To define the heterogeneity...
27.
Shen R, Postow M, Adamow M, Arora A, Hannum M, Maher C, et al.
Sci Transl Med
. 2021 Aug;
13(608).
PMID: 34433638
Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however, they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade (ICB) treatment choices are lacking....
28.
Quintanal-Villalonga A, Taniguchi H, Zhan Y, Hasan M, Chavan S, Meng F, et al.
Cancer Discov
. 2021 Jun;
11(12):3028-3047.
PMID: 34155000
Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here,...
29.
Navarrete-Dechent C, Cordova M, Aleissa S, Shoushtari A, Hollmann T, Leitao Jr M, et al.
J Dtsch Dermatol Ges
. 2021 May;
19(5):768-771.
PMID: 33979046
No abstract available.
30.
Guercio B, Iyer G, Kidwai W, Lacouture M, Ghafoor S, Rossi A, et al.
Case Rep Oncol
. 2021 Apr;
14(1):430-438.
PMID: 33790764
Metastatic primary cutaneous extramammary Paget disease (EMPD) is a rare clinical entity with a 5-year survival <10% and no standard therapy. We report the first case to our knowledge of...